- Home
- NUVL vs MUR Comparison
NUVL vs MUR Comparison
Compare NUVL & MUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- MUR
- Stock Information
- Founded
- NUVL 2017
- MUR 1950
- Country
- NUVL United States
- MUR United States
- Employees
- NUVL N/A
- MUR N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- MUR Oil & Gas Production
- Sector
- NUVL Health Care
- MUR Energy
- Exchange
- NUVL Nasdaq
- MUR Nasdaq
- Market Cap
- NUVL 4.9B
- MUR 4.7B
- IPO Year
- NUVL 2021
- MUR N/A
- Fundamental
- Price
- NUVL $87.24
- MUR $32.48
- Analyst Decision
- NUVL Strong Buy
- MUR Hold
- Analyst Count
- NUVL 10
- MUR 13
- Target Price
- NUVL $112.60
- MUR $41.08
- AVG Volume (30 Days)
- NUVL 492.9K
- MUR 1.5M
- Earning Date
- NUVL 11-12-2024
- MUR 11-07-2024
- Dividend Yield
- NUVL N/A
- MUR 3.60%
- EPS Growth
- NUVL N/A
- MUR N/A
- EPS
- NUVL N/A
- MUR 3.09
- Revenue
- NUVL N/A
- MUR $3,191,294,000.00
- Revenue This Year
- NUVL N/A
- MUR N/A
- Revenue Next Year
- NUVL N/A
- MUR $3.10
- P/E Ratio
- NUVL N/A
- MUR $10.80
- Revenue Growth
- NUVL N/A
- MUR N/A
- 52 Week Low
- NUVL $56.52
- MUR $30.99
- 52 Week High
- NUVL $113.51
- MUR $49.14
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- MUR 53.49
- Support Level
- NUVL $89.62
- MUR $31.65
- Resistance Level
- NUVL $96.24
- MUR $33.79
- Average True Range (ATR)
- NUVL 2.90
- MUR 0.87
- MACD
- NUVL -0.27
- MUR 0.26
- Stochastic Oscillator
- NUVL 15.96
- MUR 91.07
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About MUR Murphy Oil Corporation
Murphy Oil is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.